Approved for use through 10/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

s	substitute for form 1449A/PTO			Complete if Known		
				Application Number	10/593,710	
	NFORMATION DISC			Filing Date	September 21, 2006	
STATEMENT BY APPLICANT				First Named Inventor	Louise D. McCullough, et al	
				Art Unit	4682 1649	
	(Use as many sheets as ne	cessa	ry)	Examiner Name	Not Yot Accigned Haves	
Sheet	1	of	3	Attorney Docket Number	P71492US/37049.00070	

			U.S. PATENT D	OCUMENTS	
Examiner Initials	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials	IVO.	Number-Kind Code ² (if known)	MINI-DD-TTTT	Applicant of Cited Document	Figures Appear
/R.H./		US- 2005/092068	10-06-2005	McCullough et al.	
1		US- 6,423,705	01-17-2002	Tracey et al.	
V		US- 5,981,575	11-09-1999	Kuhajda et al.	
		US- 2002/0099075	07-25-2002	Tracey et al.	
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials'	Cite No.1	Foreign Patent Document Country Code ⁹ Number ⁶ Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
/R.H./		WO 2001/023399	04-05-2001	Pfizer Products, Inc et al				

Examiner Signature	/Robert Hayes/	Date Considered	06/10/2011

EXAMINER: Initial if reference considered, whether or not otation is in conformance with MPEP 600. Draw line through distion if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicant's unique clastion designation number (optional)," See Kinds Colos of USPTO Patient Documents at view subscience of view 100 of 100.1. "Enter Office that issued the document, by the two letter code (WIPO Standard ST3)," For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient document." Kind of concurrent by the appropriate symbols as indicated not the document under WIPO Standards ST.6 if possible. Applicant is to plead a check mark five it English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contained (MOR control number.

Substitute for form 1449B/PTO			Complete if Known		
Substitute	of form 1449B/PTO		Application Number	10/593,710	
IN	IFORMATION DISC	LOSURE	Filing Date	September 21, 2006	
S	TATEMENT BY AP	PLICANT	First Named Inventor	Louise D. McCullough, et al	
STATEMENT BY ATTEICANT			Art Unit	1632	
	(Use as many sheets as ne	cessary)	Examiner Name	Not Yet Assigned	
Sheet	2	<<3>>>	Attorney Docket Number	P71492US/37049.00070	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the term (book, magazine, journal, serial, symposium, catalog, dec.), date, page(s), volume-issue number(s), publisher, cty and/or country where publisher	T ²
		KIM Y. K. et al., "Expression of FAS with Hypothalamic Neurons: a Model for Decreased Food Intake after C75 treatment," Endocrinol Metab. 283, E867-E879 (2002).	
		LEON J. et al., "Modulation of Rat Striatal Glutamatergic Response in Search for New Neuroprotective Agents: Evaluation of Melatonin and Some Kynurenine Derivatives," <i>Brain Research Bulletin</i> , 45, 525-530 (2003).	
		SHENG R. et al., "EDT, a Tetrahydroacridine Derivative Inhibits Cerebral Ischemia and Protects Rat Cortical Neurous Against Glutamate-Induced Cytotoxicity," Acta Pharmacol Sin 24(5) 390-393 (May 2003).	
		CARLING, D., "The AMP-Activated Protein Kinase Cascade – a Unifying System for Energy Control," Trends in Biochemical Sciences, 29(1) 18-24 (January 2004).	
		WITTERS, L., et al., "Insulin Activation of Acetyle-CoA Carboxylase Accompaned by Inhibition of the 5'-AMP-Activated Protein Kinase," The J. of Biol. Chem., 267(5), 2864-2867 (February 1992).	
\forall		ZHIHONG, H., et al., "Effects of Cerebral Ischemia in Mice Deficient in Neuronal Nitric Oxide Synthase," Science 265, 1883-1885 (September 1994).	
no cop provid	r	ELIASSON, M. et al. "Bely (ADD ribors) Polymerase Gene Disraption Renders Mice Resistant to Cerebral Ischemia" Natura Medicina 3(10) 1089-1005 (October 1007).	
/R.H./		HAWLEY, S. et al., "Characterization of the AMP-activated Protein Kinase Kinase from Rat Liver and Identification of Theronine 172 as the Major Site at Which it Phosphorylates AMP-activated Protein Kinase," J. of Biol. Chem. 271(44), 27879-27887 (November 1996).	
		HARDIE, D. G. et al., "AMP-Activated Protein Kinase: an Ultrasensitive system for Monitoring Cellular Energy Charge," Biochem J. 338, 717-722 (1999).	
\forall		MCCULLOUGH, L. et al., "Neuroprotective Function of the PGE ₂ EP2 Receptor in Cerebral Ischemia, J. of Neuroscience 24(1) 257-268 (January 2004).	

*EXAMINER: Initial if reference considered	whether or not citation is in conformance with MPEP 609	Draw line through citation if not in conformance and not

Date

06/10/2011

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Examiner

Signature

/Robert Haves/

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 3T CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to proceed) an application. Confidentially is generated by 58. U.S. C. 122 and 3T CPR 1.1 Mis collection is not to employ to compile experiments of the complete depolar polar pola

06/10/2011

Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	10/593,710	
IN	IFORMATION DISC	LO	SURE	Filing Date	September 21, 2006	
STATEMENT BY APPLICANT			CANT	First Named Inventor	Louise D. McCullough, et al	
٠	IAILMLIII DI AI		OAII.	Art Unit	1632	
	(Use as many sheets as ne	cessa	ry)	Examiner Name	Not Yet Assigned	
Sheet	3	of	<<3>>>	Attorney Docket Number	P71492US/37049.00070	

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
/R.H./		MCCULLOUGH, L. et al. "Postischemic Estrogen Reduces Hypoperfusion and Secondary Ischemia After Experimental Stroke" Stroke 32, 796-802 (2001).	
		ZHOU, et al., "Role of AMP-activated Protein Kinase in Mechanism of Metformin Action," J. of Clinical Investigation 108(8) 1167-1174 (October 2001).	
		CORTON, et al., "5-A Minoimidazole-4-Carboxamide Ribonucleoside A Specific Method for Activating AMP-Activated Protein Kinase in Intact Cells?" Eur J. Biochem. 229, 558-565 (1995).	
Ψ		ALMEIDA, A. et al. "Nitric Oxide Switches On Glycolysis Through The AMP Protein Kinase And 6-Phosphofructo-2-Kinase Pathway," Nature Cell Bio. 6, 45-51 (January 2004).	

*EXAMINER: Initial if reference considered	whether or not citation is in conformance with MPEP 600.	Draw line through citation if not in conformance and not	

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Examiner

Signature

/Robert Hayes/

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.